Latest News

Tuesday, October 16, 2018

Phase 3 Results for Eculizumab for Treatment of Patients with Myasthenia Gravis

At the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) in Washington, DC, October 10-12, results were presented from the phase 3 REGAIN trial (NCT01997229) and the REGAIN …

Read the full story

Monday, October 15, 2018

AANEM Meeting Highlights Precision Medicine, Access to Care, and Technology for Neuromuscular Diseases

The American Association of Neuromuscular and Electrodiagnostic Medicine 34th Annual Meeting was held in Washington, DC October 10-12. The theme of the meeting was precision medicine, which included s…

Read the full story

Friday, October 12, 2018

Patisiran and Inotersen Continue to Show Efficacy and Safety in Open-Label and Expanded-Access Trials for Patients With Hereditary Transthyretin-Mediated Amyloidosis

Results from an open-label extension of the multi-center, randomized, double-blind phase 3 APOLLO study (NCT01960348) of patisiran (Onpattro; Alnylam, Cambridge, MA) and from the NEURO-TTR study (NCT0…

Read the full story

Friday, October 12, 2018

Thymectomy May be Effective Only For Some Forms of Myasthenia Gravis

Although randomized trials demonstrate that treatment with thymectomy has benefits for patients with nonthymomatous antiacetylcholine receptor (AChR) antibody positive generalized myasthenia gravis (M…

Read the full story

Friday, October 12, 2018

Cladribine Extension Trial and Post Hoc Analysis Shows 10-Year Safety and Efficacy

In data presented at the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany Oct. 10-12, real-world follow up and post-hoc analysis of cladribine (E…

Read the full story

Friday, October 12, 2018

Dimethyl Fumarate Has Low Risk of Progressive Multifocal Leukoencephalopathy, Short Duration of Lymphopenia, and Long-Term Efficacy for Relapsing Multiple Sclerosis

At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany October 10-12, results were reported from an integrated analysis of data from the DEFINE…

Read the full story

Friday, October 12, 2018

Evobrutinib—A First-in-Class Drug—Shows Efficacy in Phase 2 Clinical Trials

October 12, 2018 -- At the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, German October 10-12, results from a double-blind placebo-controlled trial (N…

Read the full story

Thursday, October 11, 2018

Alemtuzumab Has Continued Efficacy for Patients With Multiple Sclerosis After 8 years of Follow-Up

Phase 3 extension studies for alemtuzumab (Lemtrada; Sanofi-Genzyme, Cambridge, MA) has continued efficacy after 8 years of treatment according to results presented at the European Committee on Resear…

Read the full story

Thursday, October 11, 2018

Natalizumab Has Long Term Efficacy and Safety That is Well Controlled With Use of the JCV Index

In results presented at the European Committee on Treatment and Research for Multiple Sclerosis (ECTRIMS) conference in Berlin, Germany, data on the use of natalizumab (NTZ) (Tysabri; Biogen, Cambridg…

Read the full story

Thursday, October 11, 2018

Ocrelizumab Reduces Upper Limb Disability for Patients With Progressive Multiple Sclerosis

October 11, 2018 -- Results from new analysis of the phase 3 ORATORIO study (NCT01194570) were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in…

Read the full story

Wednesday, October 10, 2018

Ozanimod May Have Benefits on Cognition and Annualized Relapse Rate for Patients With Multiple Sclerosis

Results of post hoc analyses of pivotal phase 3 trials assessing the efficacy of the investigational compound ozanimod (Celgene, Summitt, NJ) versus interferon ß-1a (IFN) (Avonex; Biogen, C…

Read the full story

Wednesday, October 10, 2018

Automated Tracking of Eye Movements an Objective Biomarker of Pediatric Concussion

Researchers at the Children's Hospital of Philadelphia's (CHOP) Center for Injury Research and Prevention (CIRP) have evaluated use of eye-tracking measurements and visiovestibular evaluation …

Read the full story

Wednesday, October 10, 2018

Long-Term Efficacy of Ocrelizumab Treatment for People with Relapsing Multiple Sclerosis

Multiple results regarding use of ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for treatment of patients with multiple sclerosis (MS) were presented today at the European Committee for Tr…

Read the full story

Wednesday, October 10, 2018

Muscular Dystrophy Association Funds $9.9 Million in Research Grants

The Muscular Dystrophy Association (MDA) has announced a new round of grant funding that includes second-generation precision medicine treatments, disease-specific research networks, analysis of large…

Read the full story

Tuesday, October 09, 2018

First Patient Treated in Phase 1/2a Trial of Cell Therapy for Amyotrophic Lateral Sclerosis

The first-ever transplantation of astrocytes derived from stem cells (AstroRx; Kadimastem, Nes Ziona, Israel) into a patient with amyotrophic lateral sclerosis (ALS) has been announced. Beginning in A…

Read the full story
Load More